Altered Blood Flow Response to Small Muscle Mass Exercise in Cancer Survivors Treated With Adjuvant Therapy.
Adjuvant cancer treatments have been shown to decrease cardiac function. In addition to changes in cardiovascular risk, there are several additional functional consequences including decreases in exercise capacity and increased incidence of cancer-related fatigue. However, the effects of adjuvant cancer treatment on peripheral vascular function during exercise in cancer survivors have not been well documented. We investigated the vascular responses to exercise in cancer survivors previously treated with adjuvant cancer therapies.



Peripheral vascular responses were investigated in 11 cancer survivors previously treated with adjuvant cancer therapies (age 58±6 years, 34±30 months from diagnosis) and 9 healthy controls group matched for age, sex, and maximal voluntary contraction. A dynamic handgrip exercise test at 20% maximal voluntary contraction was performed with simultaneous measurements of forearm blood flow and mean arterial pressure. Forearm vascular conductance was calculated from forearm blood flow and mean arterial pressure. Left ventricular ejection time index (LVETi) was derived from the arterial pressure wave form. Forearm blood flow was attenuated in cancer therapies compared to control at 20% maximal voluntary contraction (189.8±53.8 vs 247.9±80.3 mL·min-1, respectively). Forearm vascular conductance was not different between groups at rest or during exercise. Mean arterial pressure response to exercise was attenuated in cancer therapies compared to controls (107.8±10.8 vs 119.2±16.2 mm Hg). LEVTi was lower in cancer therapies compared to controls.



These data suggest an attenuated exercise blood flow response in cancer survivors ≈34 months following adjuvant cancer therapy that may be attributed to an attenuated increase in mean arterial pressure.
Department of Health and Exercise Science, The University of Oklahoma, Norman, OK.|Department of Kinesiology, Kansas State University, Manhattan, KS.
Kaylin D
KD
Didier
Department of Health and Exercise Science, The University of Oklahoma, Norman, OK.
Austin K
AK
Ederer
Department of Health and Exercise Science, The University of Oklahoma, Norman, OK.
Landon K
LK
Reiter
Department of Health and Exercise Science, The University of Oklahoma, Norman, OK.
Michael
M
Brown
Department of Health and Exercise Science, The University of Oklahoma, Norman, OK.
Rachel
R
Hardy
Department of Health and Exercise Science, The University of Oklahoma, Norman, OK.|Department of Kinesiology, Kansas State University, Manhattan, KS.
Jacob
J
Caldwell
Department of Health and Exercise Science, The University of Oklahoma, Norman, OK.
Christopher
C
Black
Department of Health and Exercise Science, The University of Oklahoma, Norman, OK.
Michael G
MG
Bemben
Department of Health and Exercise Science, The University of Oklahoma, Norman, OK cade@ksu.edu.|Department of Kinesiology, Kansas State University, Manhattan, KS.
Carl J
CJ
Ade
D000368:Aged; D001783:Blood Flow Velocity / Q000502:physiology*; D001794:Blood Pressure / Q000502:physiology*; D000073116:Cancer Survivors; D016022:Case-Control Studies; D017024:Chemotherapy, Adjuvant; D003430:Cross-Sectional Studies; D015444:Exercise / Q000502:physiology; D005081:Exercise Therapy / Q000379:methods*; D005260:Female; D006801:Humans; D006973:Hypertension / Q000209:etiology / Q000503:physiopathology / Q000517:prevention & control*; D008297:Male; D008875:Middle Aged; D009119:Muscle Contraction / Q000502:physiology*; D018482:Muscle, Skeletal / Q000503:physiopathology*; D009369:Neoplasms / Q000150:complications / Q000503:physiopathology / Q000628:therapy*; D018714:Radiotherapy, Adjuvant
arterial pressure; blood flow; cancer; exercise; exercise physiology